Novel integrin-binding peptide, inhibiting hepatocyte growth factor (HGF) signaling through Met-integrin interactions, also being an antiangiogenic agent by reducing phosphorylation of VEGR2, IGFR, and PDGFR, stabilizing vessels by disrupting α5β1 signali

Novel highly potent and orally bioavailable Axl inhibitor

Novel potent dual ERK5 and BRD4 inhibitor

Novel potent and selective ERK5 inhibitor

Novel dual ERK5 and BRD4 inhibitor

Highly specific JNK inhibitor #212121; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0

Zn -dependent inhibitor of human plasma Lp-PLA2

Novel potent dual inhibitor of Ax1 and Mer

Novel specific inhibitor of HIV-1 entry through interaction with the Env spike by virtue of the incorporation of a guandinium group

Novel PDE4 inhibitor

The first potent and selective αvβ5 integrin inhibitor

Novel potent and selective αvβ3 integrin inhibitor

Potent broad spectrum antibacterial agent, particularly against drug-resistant Staphylococcus pathogens

Novel cytosolic phospholipase A2 group IVA (cPLA2α) inhibitor, displaying potent anti-inflammatory activity and disease-modifying properties in cellular and in vivo models

Natural potent antienterovirus D68 (anti-EV-D68) agent

Cancer chemoprevebtive agent

Novel antistaphyloccocal agent, attenuating inhibition of hERG potassium channel current

Novel angiotensin-(1-7) Mas receptor agonist

Novel non-peptide Ang-(1-7) mimetic, inhibiting perivascular inflammation, through the reduction of chemokine expression in pVAT, as well as through direct actions on monocytes/macrophages inhibiting their activation

The fifth-generation fluoroquinolone with in vitro coverage of community-acquired bacterial pneumonia (CABP) pathogens, atypical respiratory pathogens, multidrug-resistant Streptococcus pneumoniae and methicillin-resistant Staphylococcus aureus

Novel USP28 inhibitor

Novel selective USP7 inhibitor (USP7 IC50 9 μM; USP8 >50μM)

Novel USP28 inhibitor

First-in-class allosteric inhibitor of respiratory syncytial virus (RSV), blocking RNA elongation by the respiratory syncytial virus polymerase complex

Novel, highly potent p53-MDM2 inhibitor with an IC50 value of 0.08 nmol/L, displaying excellent oral efficacy in the human SJSA1-based xenograft model.

Novel USP28 inhibitor

Novel USP30 inhibitor

Monoselective agonist of the S1P(1) receptor

Novel anticancer agent, exhibiting potential cytotoxicity and inhibiting autophagy in hepatocellular carcinoma (HCC) cells

Novel inhibitor of autophagy, promoting metabolic stress within the tumour microenvironment and potentiating the effect of cytostatics in combination therapy